The first dedicated GLP1-RA outcome trial of patients with DKD, the FLOW trial (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease) [105], was stopped early for efficacy on 10 October 2023 [106]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.